Genomic landscape of liposarcoma

Oncotarget

Volumn 6, Issue 40, 2015, Pages 42429-42444

  Kanojia, Deepika ^a   Nagata, Yasunobu ^b   Garg, Manoj ^a   Lee, Dhong Hyun ^c   Sato, Aiko ^b   Yoshida, Kenichi ^b   Sato, Yusuke ^b   Sanada, Masashi ^b,d   Mayakonda, Anand ^a   Bartenhagen, Christoph ^e   Klein, Hans Ulrich ^e   Doan, Ngan B ^f   Said, Jonathan W ^f   Mohith, S ^a   Gunasekar, Swetha ^a   Shiraishi, Yuichi ^g   Chiba, Kenichi ^g   Tanaka, Hiroko ^g   Miyano, Satoru ^g   Myklebost, Ola ^h,i   Yang, Henry ^a   Dugas, Martin ^e   Meza Zepeda, Leonardo A ^h   Silberman, Allan W ^j   Forscher, Charles ^c   Tyner, Jeffrey W ^k   Ogawa, Seishi ^b   Phillip Koeffler, H ^a,c,l   more..

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^e UNIVERSITY OF MÜNSTER   (Germany)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF TOKYO   (Japan)

^h OSLO UNIVERSITY HOSPITAL   (Norway)

ⁱ UNIVERSITY OF OSLO   (Norway)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^l NATIONAL UNIVERSITY HOSPITAL   (Singapore)

more..

Author keywords

Exome sequencing; Intra tumor heterogeneity; Liposarcoma; SNP array; Therapeutics

Indexed keywords

ATM PROTEIN; CARBOXYPEPTIDASE; CARBOXYPEPTIDASE M; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE 4; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GENOMIC DNA; HIGH MOBILITY GROUP A2 PROTEIN; JANUS KINASE; LAMININ ALPHA4; MICRORNA 15A; MICRORNA 16; MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; PROTEIN MDM2; PROTEIN P53; SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; STAT PROTEIN; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; WNT PROTEIN; TRANSCRIPTOME;

APOPTOSIS; ARID1A GENE; ARTICLE; ATM GENE; CANCER GENETICS; CARCINOGENESIS; CDK4 GENE; CHEK1 GENE; CHEK2 GENE; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 1P; CONTROLLED STUDY; COPY NUMBER VARIATION; CPM GENE; DNA DAMAGE; DRUG RESEARCH; ERBB3 GENE; FAT3 GENE; GENE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC PROCEDURES; GENOME ANALYSIS; HMGA2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF1R GENE; IGF2 GENE; IN VITRO STUDY; IN VIVO STUDY; LAMA4 GENE; LIPOSARCOMA; MAJOR CLINICAL STUDY; MDC1 GENE; MDM2 GENE; MIR15A GENE; MIR16 1 GENE; MIR557 GENE; MOLECULARLY TARGETED THERAPY; MXRA5 GENE; NF1 GENE; ONCOGENE; PLEC GENE; POLYMERASE CHAIN REACTION; RUNX3 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TARGETED EXOME SEQUENCING; TP53 GENE; TUMOR DIFFERENTIATION; UAP1 GENE; WHOLE EXOME SEQUENCING; ANIMAL; DNA MICROARRAY; DNA MUTATIONAL ANALYSIS; FLOW CYTOMETRY; GENE SILENCING; GENETICS; HIGH THROUGHPUT SEQUENCING; MOUSE; NONOBESE DIABETIC MOUSE; SCID MOUSE; SOFT TISSUE TUMOR; XENOGRAFT;

ANIMALS; DNA MUTATIONAL ANALYSIS; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LIPOSARCOMA; MICE; MICE, INBRED NOD; MICE, SCID; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; SOFT TISSUE NEOPLASMS; TRANSCRIPTOME;

EID: 84952333753     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6464     Document Type: Article

References (50)

1. Mack TM. Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen. Cancer. 1995; 75:211-244.
2. Dalal KM, Antonescu CR and Singer S. Diagnosis and management of lipomatous tumors. Journal of surgical oncology. 2008; 97:298-313.
3. Jo VY and Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014; 46:95-104.
4. Rosai J, Akerman M, Dal Cin P, DeWever I, Fletcher CD, Mandahl N, Mertens F, Mitelman F, Rydholm A, Sciot R, Tallini G, Van den Berghe H, Van de Ven W, Vanni R and Willen H. Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP Study Group). The American journal of surgical pathology. 1996; 20:1182-1189.
5. Crozat A, Aman P, Mandahl N and Ron D. Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma. Nature. 1993; 363:640-644.
6. Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, Terrier P, Ranchere-Vince D, Collin F, Myklebost O and Turc-Carel C. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes, chromosomes & cancer. 1999; 24:30-41.
7. Barretina J, Taylor BS, Banerji S, Ramos AH, Lagos-Quintana M, Decarolis PL, Shah K, Socci ND, Weir BA, Ho A, Chiang DY, Reva B, Mermel CH, Getz G, Antipin Y, Beroukhim R, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature genetics. 2010; 42:715-721.
8. Taylor BS, DeCarolis PL, Angeles CV, Brenet F, Schultz N, Antonescu CR, Scandura JM, Sander C, Viale AJ, Socci ND and Singer S. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer discovery. 2011; 1:587-597.
9. Italiano A, Bianchini L, Keslair F, Bonnafous S, Cardot-Leccia N, Coindre JM, Dumollard JM, Hofman P, Leroux A, Mainguene C, Peyrottes I, Ranchere-Vince D, Terrier P, Tran A, Gual P and Pedeutour F. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon. International journal of cancer Journal international du cancer. 2008; 122:2233-2241.
10. Lee DH, Amanat S, Goff C, Weiss LM, Said JW, Doan NB, Sato-Otsubo A, Ogawa S, Forscher C and Koeffler HP. Overexpression of miR-26a-2 in human liposarcoma is correlated with poor patient survival. Oncogenesis. 2013; 2:e47.
11. McGwire GB and Skidgel RA. Extracellular conversion of epidermal growth factor (EGF) to des-Arg53-EGF by carboxypeptidase M. The Journal of biological chemistry. 1995; 270:17154-17158.
12. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, et al. Signatures of mutational processes in human cancer. Nature. 2013; 500:415-421.
13. Shimamori Y, Kumagai Y, Watanabe Y and Fujimoto Y. Human placental carboxypeptidase M is anchored by a glycosyl-phosphatidylinositol moiety. Biochemistry international. 1990; 20:607-613.
14. Skidgel RA, McGwire GB and Li XY. Membrane anchoring and release of carboxypeptidase M: implications for extracellular hydrolysis of peptide hormones. Immunopharmacology. 1996; 32:48-52.
15. Erickson-Johnson MR, Seys AR, Roth CW, King AA, Hulshizer RL, Wang X, Asmann YW, Lloyd RV, Jacob EK and Oliveira AM. Carboxypeptidase M: a biomarker for the discrimination of well-differentiated liposarcoma from lipoma. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2009; 22:1541-1547.
16. Tsakiris I, Soos G, Nemes Z, Kiss SS, Andras C, Szanto J and Dezso B. The presence of carboxypeptidase-M in tumour cells signifies epidermal growth factor receptor expression in lung adenocarcinomas: the coexistence predicts a poor prognosis regardless of EGFR levels. Journal of cancer research and clinical oncology. 2008; 134:439-451.
17. Zhang H, Erickson-Johnson M, Wang X, Oliveira JL, Nascimento AG, Sim FH, Wenger DE, Zamolyi RQ, Pannain VL and Oliveira AM. Molecular testing for lipomatous tumors: critical analysis and test recommendations based on the analysis of 405 extremity-based tumors. The American journal of surgical pathology. 2010; 34:1304-1311.
18. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, Dohner K, Bentz M and Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. The New England journal of medicine. 2000; 343:1910-1916.
19. Stilgenbauer S, Nickolenko J, Wilhelm J, Wolf S, Weitz S, Dohner K, Boehm T, Dohner H and Lichter P. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene. 1998; 16:1891-1897.
20. Elnenaei MO, Hamoudi RA, Swansbury J, Gruszka-Westwood AM, Brito-Babapulle V, Matutes E and Catovsky D. Delineation of the minimal region of loss at 13q14 in multiple myeloma. Genes, chromosomes & cancer. 2003; 36:99-106.
21. Dong JT, Boyd JC and Frierson HF, Jr. Loss of heterozygosity at 13q14 and 13q21 in high grade, high stage prostate cancer. Prostate. 2001; 49:166-171.
22. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102:13944-13949.
23. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19:202-208.
24. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, Mooney TB, Callaway MB, Dooling D, Mardis ER, Wilson RK and Ding L. MuSiC: identifying mutational significance in cancer genomes. Genome research. 2012; 22:1589-1598.
25. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144:646-674.
26. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012; 491:399-405.
27. Buchberg AM, Cleveland LS, Jenkins NA and Copeland NG. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature. 1990; 347:291-294.
28. Cichowski K and Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001; 104:593-604.
29. Ponti G, Martorana D, Pellacani G, Ruini C, Loschi P, Baccarani A, De Santis G, Pollio A, Neri TM, Mandel VD, Maiorana A, Maccio L, Maccaferri M and Tomasi A. NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies. Anticancer research. 2014; 34:3021-3030.
30. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417:949-954.
31. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010; 28:466-474.
32. Wabitsch M, Bruderlein S, Melzner I, Braun M, Mechtersheimer G and Moller P. LiSa-2, a novel human liposarcoma cell line with a high capacity for terminal adipose differentiation. International journal of cancer Journal international du cancer. 2000; 88:889-894.
33. Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Fujita C, Ikegami H, Ariyoshi A, Naito M, Kaneko Y and Kikuchi M. Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization. International journal of oncology. 2003; 22:535-542.
34. Snyder EL, Sandstrom DJ, Law K, Fiore C, Sicinska E, Brito J, Bailey D, Fletcher JA, Loda M, Rodig SJ, Dal Cin P and Fletcher CD. c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme. The Journal of pathology. 2009; 218:292-300.
35. Persson F, Olofsson A, Sjogren H, Chebbo N, Nilsson B, Stenman G and Aman P. Characterization of the 12q amplicons by high-resolution, oligonucleotide array CGH and expression analyses of a novel liposarcoma cell line. Cancer letters. 2008; 260:37-47.
36. Aman P, Ron D, Mandahl N, Fioretos T, Heim S, Arheden K, Willen H, Rydholm A and Mitelman F. Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11). Genes, chromosomes & cancer. 1992; 5:278-285.
37. Braas D, Ahler E, Tam B, Nathanson D, Riedinger M, Benz MR, Smith KB, Eilber FC, Witte ON, Tap WD, Wu H and Christofk HR. Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment. Cancer discovery. 2012; 2:1109-1117.
38. Stratford EW, Castro R, Daffinrud J, Skarn M, Lauvrak S, Munthe E and Myklebost O. Characterization of liposarcoma cell lines for preclinical and biological studies. Sarcoma. 2012; 2012:148614.
39. Maciejewski JP, Tiu RV and O'Keefe C. Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. British journal of haematology. 2009; 146:479-488.
40. Bengtsson H, Wirapati P and Speed TP. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics. 2009; 25:2149-2156.
41. Hupe P, Stransky N, Thiery JP, Radvanyi F and Barillot E. Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics. 2004; 20:3413-3422.
42. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R and Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome biology. 2011; 12:R41.
43. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, Sato Y, Sato-Otsubo A, Kon A, Nagasaki M, Chalkidis G, Suzuki Y, Shiosaka M, Kawahata R, Yamaguchi T, Otsu M, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478:64-69.
44. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nature genetics. 2013; 45:860-867.
45. Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M, Kon A, Sanada M, Chiba K, Tanaka H, Makishima H, Wang X, Xu Y, Doisaki S, Hama A, Nakanishi K, et al. Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nature genetics. 2013; 45:937-941.
46. Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, Sanada M, Park MJ, Terui K, Suzuki H, Kon A, Nagata Y, Sato Y, Wang R, Shiba N, Chiba K, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nature genetics. 2013; 45:1293-1299.
47. Wendl MC, Wallis JW, Lin L, Kandoth C, Mardis ER, Wilson RK and Ding L. PathScan: a tool for discerning mutational significance in groups of putative cancer genes. Bioinformatics. 2011; 27:1595-1602.
48. Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. The New England journal of medicine. 2009; 361:1058-1066.
49. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L and Wilson RK. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome research. 2012; 22:568-576.
50. Olshen AB, Venkatraman ES, Lucito R and Wigler M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 2004; 5:557-572.